ACB
Aurora Cannabis Inc.
ACB's outlook is improving, though it still trails on the overall score.
UNH
UnitedHealth Group Incorporated
UNH has the edge over ACB overall, supported by stronger fundamentals and lower modeled downside.
ACB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
ACB's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ACB PE Valuation
ACB has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ACB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Improving | |
| Limited | |
| High |
ACB has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ACB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.36 | -500% |
| Q1 2026 | -$0.91 | -2375% |
| Q4 2025 | -$0.53 | -431% |
| Q3 2025 | -$0.14 | +$0.47 |
| Q2 2025 | $0.34 | +$0.80 |
| Q1 2025 | $0.04 | +$1.18 |
| Q4 2024 | $0.16 | +$2.37 |
| Q3 2024 | -$0.61 | +$2.63 |
ACB has swung to a loss: it lost $1.36 per share over the past year, after a profit the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ACB on earnings quality, reporting a profit while its opponent remains loss making.
ACB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $47.5M | -23% |
| Q1 2026 | $26.8M | -58% |
| Q4 2025 | $66.2M | +6.8% |
| Q3 2025 | $63.5M | +11% |
| Q2 2025 | $62M | +5.7% |
| Q1 2025 | $63.7M | +34% |
| Q4 2024 | $62M | +37% |
| Q3 2024 | $57M | +29% |
ACB's revenue is shrinking: $48M last quarter, down 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -70% | -112 points |
| Q1 2026 | -66% | -33 points |
| Q4 2025 | 5.1% | -37 points |
| Q3 2025 | -20% | -17 points |
| Q2 2025 | 42% | +41 points |
| Q1 2025 | -34% | -38 points |
| Q4 2024 | 42% | +69 points |
| Q3 2024 | -3% | +14 points |
ACB's operating margin was −70% last quarter, down 112 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ACB on profitability, with a higher operating margin.
ACB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.9M | -294% |
| Q1 2026 | -$3.8M | -$3.4M |
| Q4 2025 | $7.7M | -54% |
| Q3 2025 | -$32.9M | -$12.2M |
| Q2 2025 | $3.6M | +58% |
| Q1 2025 | -$438K | +$18.4M |
| Q4 2024 | $16.9M | +$22.5M |
| Q3 2024 | -$20.7M | +$4M |
ACB has burned cash in most quarters: −$36M over the past year, against −$702,335 the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ACB on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.3% | +4.2M shares |
| 1 year | +11% | +5.9M shares |
| 3 years | +74% | +26.3M shares |
| 5 years | +212% | +41.9M shares |
| Available history | +612% | +53M shares |
ACB has 62M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ACB hasn't bought back shares in the past year.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ACB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ACB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -6.1x | Net Cash |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
| Q3 2024 | -4.5x | Net Cash |
| Q2 2024 | -5.2x | Net Cash |
| Q4 2023 | -0.2x | Net Cash |
ACB has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ACB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.6 | Neutral |
| Stochastic | 84.8 | Overbought |
ACB's weekly RSI is 65 (neutral) and its Stochastic is 85 (overbought).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ACB PE vs Healthcare Sector
| Metric | ACB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ACB has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ACB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.33 | 15% above |
| 20 week MA | $3.72 | 34% above |
| 50 week MA | $3.73 | 34% above |
| 100 week MA | $4.26 | 17% above |
| 200 week MA | $5.00 | 0.2% below |
ACB has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 0.2% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
ACB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $229.2 | $88.7 | -61% |
| 2021 | $88.7 | $61.2 | -31% |
| 2022 | $61.2 | $9.27 | -85% |
| 2023 | $9.27 | $4.76 | -49% |
| 2024 | $4.76 | $4.30 | -9.7% |
| 2025 | $4.30 | $4.49 | +4.4% |
| 2026 YTD | $4.49 | $4.99 | +11% |
ACB has finished lower in five of the last six years. It's up 11% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ACB on returns for 2026, with the stronger performance.